Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN)Luca Durelli, Mauro Zaffaroni, Pierangelo Barbero et al.|The Lancet|2002Cited by 552